Manage episode 230145914 series 2394758
Biogen's shares fell 30% because it's bailing on a once-promising Alzheimer's disease drug, but it might not be a bargain worth buying yet. Also, why a shareholder revolt could cause Bristol-Myers and Celgene's merger to fall apart.
Check out more of our content here:
1391 episodes available. A new episode about every day averaging 28 mins duration .